renal cell carcinoma

You have access
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study
Cristian Udovicich, Mathias Bressel, Jamil Manji, Muhammad Ali, Lewis Au, Arun A. Azad, James P. Buteau, Sarat Chander, David Chang, Renu Eapen, Nathan Lawrentschuk, Sidney M. Levy, Daniel Moon, Declan G. Murphy, Marlon Perera, Mark Shaw, Lavinia Spain, Ben Tran, Michael S. Hofman and Shankar Siva

Journal of Nuclear Medicine April 1, 2025, 66 (4) 531-536; DOI: https://doi.org/10.2967/jnumed.124.268639
Open Access
Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis
Moe S. Sadaghiani, Saradha Baskaran, Michael A. Gorin, Steven P. Rowe, Jean-Claude Provost, Iryna Teslenko, Roman Bilyk, Hong An and Sara Sheikhbahaei

Journal of Nuclear Medicine July 1, 2024, 65 (7) 1007-1012; DOI: https://doi.org/10.2967/jnumed.124.267417
You have access
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers
Marinus J. Hagens, Pim J. van Leeuwen, Maurits Wondergem, Thierry N. Boellaard, Francesco Sanguedolce, Daniela E. Oprea-Lager, Axel Bex, André N. Vis, Henk G. van der Poel and Laura S. Mertens; in collaboration with the EAU Section of Urological Imaging

Journal of Nuclear Medicine June 1, 2024, 65 (6) 888-896; DOI: https://doi.org/10.2967/jnumed.123.267260
You have access
Diagnostic Accuracy of ^99mTc-Sestamibi SPECT/CT for Characterization of Solid Renal Masses
Ashwin Singh Parihar, Joyce Mhlanga, Carrie Ronstrom, Lisa R. Schmidt, Robert S. Figenshau, Farrokh Dehdashti and Richard L. Wahl

Journal of Nuclear Medicine January 1, 2023, 64 (1) 90-95; DOI: https://doi.org/10.2967/jnumed.122.264329
You have access
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
Roberto A. Salas Fragomeni, Tali Amir, Sara Sheikhbahaei, Susan C. Harvey, Mehrbod S. Javadi, Lilja B. Solnes, Ana P. Kiess, Mohamad E. Allaf, Martin G. Pomper, Michael A. Gorin and Steven P. Rowe

Journal of Nuclear Medicine June 1, 2018, 59 (6) 871-877; DOI: https://doi.org/10.2967/jnumed.117.203570
You have access
⁸⁹Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma
Suzanne C. van Es, Adrienne H. Brouwers, Shekar V.K. Mahesh, Annemarie M. Leliveld-Kors, Igle J. de Jong, Marjolijn N. Lub-de Hooge, Elizabeth G.E. de Vries, Jourik A. Gietema and Sjoukje F. Oosting

Journal of Nuclear Medicine June 1, 2017, 58 (6) 905-910; DOI: https://doi.org/10.2967/jnumed.116.183475
You have access
Whole-Body PET/CT Evaluation of Tumor Perfusion Using Generator-Based ⁶²Cu-Ethylglyoxal Bis(Thiosemicarbazonato)Copper(II): Validation by Direct Comparison to ¹⁵O-Water in Metastatic Renal Cell Carcinoma
James W. Fletcher, Theodore F. Logan, Jacob A. Eitel, Carla J. Mathias, Yen Ng, Jeffrey L. Lacy, Gary D. Hutchins and Mark A. Green

Journal of Nuclear Medicine January 1, 2015, 56 (1) 56-62; DOI: https://doi.org/10.2967/jnumed.114.148106
You have access
⁸⁹Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
Sjoukje F. Oosting, Adrienne H. Brouwers, Suzanne C. van Es, Wouter B. Nagengast, Thijs H. Oude Munnink, Marjolijn N. Lub-de Hooge, Harry Hollema, Johan R. de Jong, Igle J. de Jong, Sanne de Haas, Stefan J. Scherer, Wim J. Sluiter, Rudi A. Dierckx, Alfons H.H. Bongaerts, Jourik A. Gietema and Elisabeth G.E. de Vries

Journal of Nuclear Medicine January 1, 2015, 56 (1) 63-69; DOI: https://doi.org/10.2967/jnumed.114.144840
You have access
Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Mark Rijpkema, Gerben M. Franssen, Egbert Oosterwijk, Peter F.A. Mulders, Wim J.G. Oyen and Otto C. Boerman

Journal of Nuclear Medicine June 1, 2014, 55 (6) 1035-1040; DOI: https://doi.org/10.2967/jnumed.114.137356
You have access
Tyrosine Kinase Inhibitor Sorafenib Decreases ¹¹¹In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders and Wim J.G. Oyen

Journal of Nuclear Medicine February 1, 2014, 55 (2) 242-247; DOI: https://doi.org/10.2967/jnumed.113.131110

Main menu

User menu

Search

renal cell carcinoma